Northwest & Ethical Investments L.P. Raises Stock Holdings in Bausch Health Companies Inc. (NYSE:BHC)

Northwest & Ethical Investments L.P. lifted its holdings in shares of Bausch Health Companies Inc. (NYSE:BHC) by 119.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,139 shares of the company’s stock after purchasing an additional 38,755 shares during the quarter. Northwest & Ethical Investments L.P.’s holdings in Bausch Health Companies were worth $574,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Goldentree Asset Management LP grew its holdings in shares of Bausch Health Companies by 31.0% during the third quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company’s stock worth $239,552,000 after purchasing an additional 6,958,717 shares in the last quarter. Bank of Montreal Can grew its holdings in shares of Bausch Health Companies by 234.0% during the third quarter. Bank of Montreal Can now owns 3,833,179 shares of the company’s stock worth $31,598,000 after purchasing an additional 2,685,675 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Bausch Health Companies by 62.0% during the fourth quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company’s stock worth $26,614,000 after purchasing an additional 1,263,706 shares in the last quarter. Maple Rock Capital Partners Inc. purchased a new position in shares of Bausch Health Companies during the third quarter worth about $16,850,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Bausch Health Companies by 1.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,284,036 shares of the company’s stock worth $10,375,000 after purchasing an additional 14,558 shares in the last quarter. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on BHC shares. Jefferies Financial Group restated a “hold” rating and issued a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. Royal Bank of Canada dropped their target price on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $7.42.

Bausch Health Companies Stock Performance

NYSE:BHC opened at $7.17 on Friday. The firm has a market cap of $2.64 billion, a PE ratio of -59.70, a price-to-earnings-growth ratio of 0.37 and a beta of 0.59. Bausch Health Companies Inc. has a fifty-two week low of $3.96 and a fifty-two week high of $11.46. The business has a 50 day moving average price of $7.14 and a 200-day moving average price of $7.68.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.44). The company had revenue of $2.56 billion for the quarter, compared to analysts’ expectations of $2.51 billion. Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. Research analysts predict that Bausch Health Companies Inc. will post 4.41 EPS for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.